Neuroendocrine Tumor

Correlatives:
No Trials Currently Available

Treatment of Advanced Neuroendocrine Tumors
- IRB# 22591 Preoperative PRRT versus surgical cytoreduction alone in metastatic pancreatic neuroendocrine tumors to the liver: a Phase II multi-institutional trial
- IRB# 23825 Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
- IRB# 23106 A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Treatment of Carcinoid Syndrome
- IRB# 19669 Study 19669 Telotristat Ethyl Grade 1/Grade 2 confirmed Small Bowel NET

CROSS-DISEASE TRIALS:
- IRB# TBD EAY131 (MATCH)

KEY
- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result